Codebase Ventures Inc (CSE:CODE) (OTCQB:BKLLF) on Wednesday provided an update on its strategy toward the development of a transdermal delivery system for hydroxychloroquine as a potential treatment for patients with coronavirus (COVID-19).
The company noted that the US National Institutes of Health (NIH) have launched a Phase IIb double-blind clinical trial to study hydroxychloroquine and azithromycin treatments in patients with COVID-19.
The main objective of the study is to determine whether the drug combo can prevent hospitalization and death. Additionally, investigators will evaluate the safety and tolerability of the experimental treatment for people infected with SARS-CoV-2, the virus that causes the COVID-19 disease.
READ: Codebase Ventures says World High Life subsidiary has advanced product development cycle to meet rising demand for CBD in UK
Codebase also pointed out that US President Donald Trump has announced that he himself is taking hydroxychloroquine as a precaution.
The company recently acquired 49% of a private pharmaceutical company which has recently filed for two US provisional patents for transdermal delivery and oral mucosal delivery of chloroquine (CQ) and hydroxychloroquine.
The private pharmaceutical company has a lab services agreement with Reformulation Research Laboratories Inc (RRL), which has led to the development of the patent applications and the underlying technology.
Codebase has stressed that it is not making any express or implied claims that chloroquine and hydroxychloroquine have any effect in the prevention or treatment of COVID-19 at this time.
Developing a transdermal or oral mucosal delivery of these drugs could help patients suffering from other diseases and viruses, the company said, noting that such technologies could lead to lower dosages and common side effects felt by patients for their on-label treatment for lupus, rheumatoid arthritis and malaria.
Contact the author: [email protected]
Follow him on Twitter @PatrickMGraham